KCK Ltd. sells $49.5 million in NeuroPace stock

Published 20/02/2025, 15:54
KCK Ltd. sells $49.5 million in NeuroPace stock

KCK LTD., a significant shareholder in NeuroPace Inc (NASDAQ:NPCE), has sold a substantial portion of its holdings in the company. According to a recent filing with the Securities and Exchange Commission, KCK LTD. disposed of 5,270,845 shares of NeuroPace common stock on February 20, 2025. The shares were sold at a price of $9.40 each, resulting in a total transaction value of approximately $49.5 million. The sale comes amid strong recent performance, with the stock showing an 86% gain over the past six months and trading near $13 currently. According to InvestingPro analysis, the stock appears overvalued at current levels.

Following this transaction, KCK LTD. no longer holds any shares of NeuroPace, as indicated in the filing. The sale was executed under direct ownership, as noted in the report. With the company’s next earnings report due on March 5, InvestingPro subscribers can access 8 additional key insights and a comprehensive Pro Research Report. NeuroPace, headquartered in Mountain View, California, specializes in surgical and medical instruments and apparatus, maintaining strong liquidity with a current ratio of 5.59.

In other recent news, NeuroPace Inc. announced plans for a $65 million public stock offering, with an additional option for underwriters to purchase extra shares. The proceeds are intended to repurchase shares from significant shareholder KCK Ltd. and support general corporate needs. The company’s audit committee has approved the repurchase arrangement, and the transaction will follow the equity offering’s completion. In analyst updates, UBS initiated coverage on NeuroPace with a Buy rating and a $17.00 price target, citing optimism about the company’s revenue growth potential and market expansion. UBS projects a compound annual growth rate of approximately 22% from 2024 to 2029, slightly above the consensus estimate. JPMorgan maintained its Overweight rating and raised its price target to $14.00, highlighting the RNS system’s clinical superiority and potential for market growth. JPMorgan anticipates a growth rate of over 15% through 2029, driven by the RNS system’s unique capabilities. These developments position NeuroPace as a company to watch in the epilepsy treatment market.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.